Shen Xiaojian, Xie Jing, Liu Shu, Cai Yun, Yuan Shen, Uehara Yuji, Zhu Dongbing, Zheng Miaosen
Department of Pathology, The People's Hospital of Rugao, Rugao Hospital Affiliated to Nantong University, Rugao, China.
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Honkomagoame, Tokyo, Japan.
J Thorac Dis. 2024 Aug 31;16(8):5361-5378. doi: 10.21037/jtd-24-1123. Epub 2024 Aug 28.
Lung adenocarcinoma (LUAD) is one of the most common malignant tumors with high mortality. Anoikis resistance is an important mechanism of tumor cell proliferation and migration. Our research is devoted to exploring the role of anoikis in the diagnosis, classification, and prognosis of LUAD.
We downloaded the expression profile, mutation, and clinical data of LUAD from The Cancer Genome Atlas (TCGA) database. The "ConsensusClusterPlus" package was then used for the cluster analysis, and least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were used to establish the prognostic model. We verified the reliability of the model using a Gene Expression Omnibus (GEO) data set. A gene set variation analysis (GSVA) was conducted to investigate the functional enrichment differences in the different clusters and risk groups. The CIBERSORT algorithm and a single-sample gene set enrichment analysis (ssGSEA) were used to analyze immune cell infiltration. The tumor mutation burden (TMB) and Tumor Immune Dysfunction and Exclusion (TIDE) scores were used to evaluate the patients' sensitivity to immunotherapy. Immunohistochemical staining of tissue microarrays was used to verify the correlation between ANGPTL4 expression and the clinicopathological characteristics and prognosis of LUAD patients.
First, we screened 135 differentially expressed anoikis-related genes (ARGs) and 23 prognosis-related ARGs from TCGA-LUAD data set. Next, 494 LUAD samples were allocated to cluster A and cluster B based on the 23 prognosis-related ARGs. The Kaplan-Meier (K-M) analysis showed the overall survival (OS) of cluster B was better than that of cluster A. The clinicopathological characteristics and functional enrichment analyses revealed significant differences between clusters A and B. The tumor microenvironment (TME) analysis showed that cluster B had more immune cell infiltration and a higher TME score than cluster A. Subsequently, a LASSO Cox regression model of LUAD was constructed with ten ARGs. The K-M analysis showed that the low-risk patients had longer OS than the high-risk patients. The receiver operating characteristic curve, nomogram, and GEO data set verification results showed that the model had high accuracy and reliability. The level of immune cell infiltration and TME score were higher in the low-risk group than the high-risk group. The high-risk group had stronger sensitivity to immune checkpoint block therapy and weaker sensitivity to chemotherapy drugs than the low-risk group. ANGPTL4 expression was correlated with stage, tumor differentiation, tumor size, lymph node metastasis, and OS.
We discovered novel molecular subtypes and constructed a novel prognostic model of LUAD. Our findings provide important insights into subtype classification and the accurate survival prediction of LUAD. We also identified ANGPTL4 as a prognostic indicator of LUAD.
肺腺癌(LUAD)是最常见且死亡率高的恶性肿瘤之一。失巢凋亡抗性是肿瘤细胞增殖和迁移的重要机制。我们的研究致力于探索失巢凋亡在LUAD诊断、分类和预后中的作用。
我们从癌症基因组图谱(TCGA)数据库下载了LUAD的表达谱、突变和临床数据。然后使用“ConsensusClusterPlus”软件包进行聚类分析,并使用最小绝对收缩和选择算子(LASSO)及多变量Cox回归分析来建立预后模型。我们使用基因表达综合数据库(GEO)数据集验证了该模型的可靠性。进行基因集变异分析(GSVA)以研究不同聚类和风险组中的功能富集差异。使用CIBERSORT算法和单样本基因集富集分析(ssGSEA)来分析免疫细胞浸润。使用肿瘤突变负荷(TMB)和肿瘤免疫功能障碍与排除(TIDE)评分来评估患者对免疫治疗的敏感性。采用组织芯片免疫组化染色验证血管生成素样蛋白4(ANGPTL4)表达与LUAD患者临床病理特征及预后的相关性。
首先,我们从TCGA-LUAD数据集中筛选出135个差异表达的失巢凋亡相关基因(ARGs)和23个预后相关ARGs。接下来,基于这23个预后相关ARGs将494个LUAD样本分为A组和B组。Kaplan-Meier(K-M)分析显示B组的总生存期(OS)优于A组。临床病理特征和功能富集分析显示A组和B组之间存在显著差异。肿瘤微环境(TME)分析显示B组比A组有更多的免疫细胞浸润和更高的TME评分。随后,用10个ARGs构建了LUAD的LASSO Cox回归模型。K-M分析显示低风险患者的OS比高风险患者长。受试者工作特征曲线、列线图和GEO数据集验证结果表明该模型具有较高的准确性和可靠性。低风险组的免疫细胞浸润水平和TME评分高于高风险组。高风险组对免疫检查点阻断治疗的敏感性强于低风险组,而对化疗药物的敏感性弱于低风险组。ANGPTL4表达与分期、肿瘤分化、肿瘤大小、淋巴结转移和OS相关。
我们发现了LUAD新的分子亚型并构建了新的预后模型。我们的研究结果为LUAD的亚型分类和准确的生存预测提供了重要见解。我们还将ANGPTL4鉴定为LUAD的预后指标。